Eli Lilly & Co. is selling Zepbound vials at $399 a month, providing a cheaper option amid supply shortages for their popular weight-loss drug.
Zepbound's vials allow patients to fill syringes themselves, saving Lilly production time and helping to ramp up supply amidst increasing demand.
While the move to vials could positively offset Lilly's sales, it also places pressure on rival Novo Nordisk, struggling with its own drug supply.
The obesity drug market is projected to expand to $130 billion by the decade's end, prompting concentrated efforts from companies like Lilly and Novo.
Collection
[
|
...
]